$Treatment of refractory immune-mediated necrotizing myopathy with efgartigimod$

Treatment of refractory immune-mediated necrotizing myopathy with efgartigimod

ObjectiveWe aimed to explore the efficacy and safety of efgartigimod in patients with refractory immune-mediated necrotizing myopathy (IMNM).MethodsThis open-label pilot observational study included seven patients with refractory IMNM, all of whom received intravenous efgartigimod treatment. The cli...

Full description

Saved in:

Bibliographic Details
Main Authors:	MengTing Yang, JingChu Yuan, YiKang Wang, HongJun Hao, Wei Zhang, ZhaoXia Wang, Yun Yuan, YaWen Zhao
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-10-01
Series:	Frontiers in Immunology
Subjects:	immune-mediated necrotizing myopathy efgartigimod refractory anti-signal recognition particle anti-3-hydroxy-3-methylglutaryl-CoA reductase
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1447182/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Statin-associated muscle disorders
by: Alan Xu, et al.
Published: (2020-01-01)

Deficiência da 3-OH-3-metil-glutaril-CoA-liase como causa de coma no período neonatal: relato de caso 3-hydroxy-3-methylglutaryl-CoA-lyase deficiency as coma etiology in the neonatal period: case report
by: ERASMO BARBANTE CASELLA, et al.
Published: (1998-09-01)

Efgartigimod combined with steroids as a fast-acting therapy for anti-SRP immune-mediated necrotizing myopathy
by: Qiqi Peng, et al.
Published: (2025-05-01)

3-Hydroxy-3-methylglutaryl-CoA reductase variants strongly associated with low-density lipoprotein cholesterol levels and diabetes mellitus risk in a Taiwanese population: A Mendelian randomization study
by: Lung-An Hsu, et al.
Published: (2025-04-01)

Successful sequential treatment with ofatumumab followed by efgartigimod for refractory autoimmune encephalitis with dual anti-NMDAR and anti-GFAP antibody positivity: first case report
by: Xin Tu, et al.
Published: (2025-08-01)

Case report: Rapid clinical improvement of anti-HMGCR immune-mediated necrotizing myopathy treated with efgartigimod
by: Quantao Zeng, et al.
Published: (2024-11-01)

Improving Cofactor Promiscuity of HMG-CoA Reductase from <i>Ruegeria pomeroyi</i> Through Rational Design
by: Haizhao Xue, et al.
Published: (2025-07-01)

Simvastatin therapy in patients with hepatic disease
by: O. M. Drapkina, et al.
Published: (2007-10-01)

Successful treatment with efgartigimod as an add-on therapy for acute attack of anti-NMDA receptor encephalitis: a case report
by: Huasheng Huang, et al.
Published: (2025-01-01)

Treatment of refractory pemphigus vulgaris with efgartigimod
by: Matthew Helm, MD, et al.
Published: (2025-07-01)

The efficacy and safety of efgartigimod for refractory myasthenia gravis: a systematic review and meta-analysis
by: Jia-Jun Cheng, et al.
Published: (2025-08-01)

Effect of selenium on main active component contents of Ganoderma lingzhi in different periods
by: YE Liyun, et al.
Published: (2017-07-01)

Diabetogenic effect of statins: a comprehensive review on the clinical relevance, underlying pathomechanisms and rationale for tailored statin therapy
by: Małgorzata Ostrowska, et al.
Published: (2015-12-01)

Virtual screening and evaluation of bioactive peptides from Haliotis discus hannai as potential HMGCR inhibitors for hyperlipidemia treatment
by: Kun Qiao, et al.
Published: (2024-12-01)

Case Report: A myasthenia gravis patient complicated with renal failure was effectively treated with efgartigimod
by: Jia Ke, et al.
Published: (2025-03-01)

Efgartigimod therapy for immune checkpoint inhibitor–associated myasthenia gravis with myositis: a case report
by: Feiteng Qi, et al.
Published: (2025-07-01)

Case Report: Therapeutic effect of efgartigimod in refractory anti-GQ1b antibody syndrome coexisting with myasthenia gravis
by: Keiko Watanabe, et al.
Published: (2025-06-01)

Short-term treatment of CIDP with efgartigimod: a case series in China
by: Chong Sun, et al.
Published: (2025-05-01)

A real-world pharmacovigilance study of efgartigimod alfa in the FDA adverse event reporting system database
by: Yunlin Yang, et al.
Published: (2025-04-01)

Real world study in Italian public hospital with Efgartigimod in patients affected by generalized myasthenia gravis: influence of clinical and serological factors
by: Manlio Sgarzi, et al.
Published: (2025-05-01)

Efgartigimod Followed by Telitacicept in Adult Generalized Myasthenia Gravis: A Retrospective Case Series
by: Zhang Y, et al.
Published: (2025-04-01)

Clinical efficacy of efgartigimod combined with intravenous methylprednisolone in the acute phase of neuromyelitis optica spectrum disorders
by: Wenjing Yang, et al.
Published: (2024-12-01)

Fast-acting treatment of myasthenic crisis with efgartigimod from the perspective of the neuro intensive care unit
by: Fangyi Shi, et al.
Published: (2025-02-01)

Efgartigimod as a fast-acting treatment in generalized very-late-onset myasthenia gravis
by: Zhouao Zhang, et al.
Published: (2025-04-01)

ADAPT NXT: Fixed Cycles or Every‐Other‐Week IV Efgartigimod in Generalized Myasthenia Gravis
by: Ali A. Habib, et al.
Published: (2025-06-01)

Case report: Efgartigimod is a novel therapeutic option for ocular myasthenia gravis: a report of 2 cases
by: Tianying Ma, et al.
Published: (2025-01-01)

Real-World Experience with FcRn Inhibitors Efgartigimod and Rozanolixizumab in Myasthenia Gravis: Administration in Multiple Cycles and Transition from Intravenous to Subcutaneous Formulation
by: Masaaki Yoshikawa, et al.
Published: (2025-04-01)

Effects of efgartigimod treatment on humoral and cellular immune responses: analysis of T-cell-dependent antibody response in cynomolgus monkeys
by: Ornella Binazon, et al.
Published: (2025-12-01)

Dissecting the Molecular Mechanism of 10-HDA Biosynthesis: Role of Acyl-CoA Delta(11) Desaturase and Transcriptional Regulators in Honeybee Mandibular Glands
by: Yunchang Li, et al.
Published: (2025-05-01)

Anti-Inflammatory Potential of 3-Hydroxy-β-Ionone from <i>Moringa oleifera:</i> Decreased Transendothelial Migration of Monocytes Through an Inflamed Human Endothelial Cell Monolayer by Inhibiting the IκB-α/NF-κB Signaling Pathway
by: Thitiya Luetragoon, et al.
Published: (2024-12-01)

Persistent dyslipidemia in statin-treated patients: Russian real-world clinical practice data (Russian part of the DYSIS Study)
by: R. G. Oganov, et al.
Published: (2012-08-01)

Discovery of novel favipiravir derivatives with improved pharmacokinetic properties as anti-SFTSV agents
by: Xiaomeng He, et al.
Published: (2024-12-01)

Specific FAHFAs predict worsening glucose tolerance in non-diabetic relatives of people with Type 2 diabetes
by: Ismail Syed, et al.
Published: (2025-07-01)

Oxysophocarpine suppresses hepatocellular carcinoma growth and sensitizes the therapeutic blockade of anti‐Lag‐3 via reducing FGL1 expression
by: Jianchu Wang, et al.
Published: (2020-10-01)

Clinical characteristics and outcome in patients with anti-AMPAR2 encephalitis: a case series and literature review
by: Congcong Wang, et al.
Published: (2025-07-01)

Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHB-HV) impregnated with mango leaves extracts using supercritical solvent impregnation
by: Ludisbel León-Marcos, et al.
Published: (2025-05-01)

Anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor encephalitis presenting as catatonia
by: Yuki Nakagawa, et al.
Published: (2025-07-01)

Genome‑wide identification of the cotton FAR gene family reveals GhFAR3 as a positive regulator of Verticillium dahliae resistance
by: Wenhan Cheng, et al.
Published: (2025-07-01)

Modulating the gut microbiota and inflammation is involved in the effect of diosgenin against diabetic nephropathy in rat
by: Jiang Shanshan, et al.
Published: (2025-05-01)

Pancrelipase as Adjunctive Therapy in Severe SCOT Deficiency: A Case of a Novel OXCT1 Gene Deletion
by: Mo'ath Abu Hamdeh, et al.
Published: (2025-05-01)